Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin ...
Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo ...
Bryn Mar Athletics16 小时
Stress and the Brain: Uncovering Sex Differences in Cognitive Flexibility
The National Institute of Mental Health awards a $344,589 grant to Associate Professor and Behavioral Neuroscientist Laura ...
The American Journal of Managed Care6 天
Novel Orexin 2 Receptor Agonist Shows Promise for Management of Narcolepsy and Idiopathic ...
Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock Institute of Medical Research, discusses the ...
Cause of SIDS is identified
Researchers at The Children's Hospital at Westmead say they've discovered babies who die from Sudden Infant Death Syndrome ...
How a Tamil Refugee Became a Medical Researcher
Researchers at The Children's Hospital at Westmead say they've discovered babies who die from Sudden Infant Death Syndrome ...
Stifel将Alkermes目标价上调至36美元，评级上调至买入
周一，Stifel对Alkermes (NASDAQ:ALKS)采取了看多行动，将其股票评级从持有上调至买入，并将目标价从之前的25美元大幅上调至36美元。这次上调是在对公司的orexin项目，特别是ALKS2680候选药物进行深入分析后做出的。 Stifel分析师强烈相信ALKS2680在治疗1型嗜睡症（NT1）方面的潜在成功，以及其与竞争对手TAK-861的差异化。这种乐观情绪还延伸到ALKS ...
Centessa Pharmaceuticals首席商务官出售价值180,628美元的股份
Centessa Pharmaceuticals plc (NASDAQ:CNTA)的首席商务官Gregory M. Weinhoff报告出售了11,742股普通股，总价值180,628美元。这些股份以15.3831美元的加权平均价格出售，交易价格范围在15.13美元至15.60美元之间。此次交易后，Weinhoff持有183,266股。这些销售是根据2024年5月22日采用的Rule 10b5- ...
来自MSN6 天
男女疼痛体验或有不同
研究人员使用来自小鼠、猴子和人类的组织，研究了两种可以使神经细胞对疼痛敏感的物质的影响：一种激素称为催乳素和一种神经递质称为Orexin B。当神经细胞检测到这些物质时，它们对刺激变得更加敏感，降低了细胞向大脑发送电信号以表明出现问题的阈值。
Life with narcolepsy: ‘It’s not a joke, it’s a very serious illness’
Imagine repeatedly falling asleep or falling down paralyzed when laughing or startled. This is life with narcolepsy, which ...
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and ...
Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely ...
Business Insider1 天
Alkermes price target raised to $31 from $28 at BofA
In the firm’s discussion in a sleep expert call previewing orexin data in 2025, BofA plans to focus on expectations for Alkermes and Centessa’s (CNTA) respective Phase 2 data updates in narcolepsy in ...